AFC Gamma (NASDAQ:AFCG) Director Leonard Tannenbaum Buys 44,914 Shares

AFC Gamma Inc. (NASDAQ:AFCG) Director Leonard Tannenbaum acquired 44,914 shares of the stock in a transaction on Tuesday, March 24th. The stock was bought at an average price of $2.59 per share, with a total value of $116,327.26. Following the completion of the acquisition, the director directly owned 6,373,106 shares of the company’s stock, valued at $16,506,344.54. This trade represents a 0.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

AFC Gamma Stock Performance

AFC Gamma stock opened at $2.61 on Thursday. AFC Gamma Inc. has a fifty-two week low of $2.06 and a fifty-two week high of $6.38. The stock’s 50 day simple moving average is $2.42 and its two-hundred day simple moving average is $3.02. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.45 and a current ratio of 3.45. The stock has a market cap of $61.41 million, a price-to-earnings ratio of -2.75 and a beta of 1.02.

AFC Gamma (NASDAQ:AFCG) last announced its earnings results on Wednesday, March 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.18). The firm had revenue of $8.71 million during the quarter, compared to the consensus estimate of $5.36 million. AFC Gamma had a positive return on equity of 0.99% and a negative net margin of 70.17%. As a group, analysts expect that AFC Gamma Inc. will post 1.64 earnings per share for the current fiscal year.

AFC Gamma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st will be issued a $0.05 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.20 dividend on an annualized basis and a yield of 7.7%. AFC Gamma’s dividend payout ratio is -55.79%.

Key Headlines Impacting AFC Gamma

Here are the key news stories impacting AFC Gamma this week:

• Positive Sentiment: Director Leonard M. Tannenbaum bought additional AFCG stock across three transactions (Mar 20, 23, 24), acquiring about 174,517 shares for roughly $447k total and raising his stake to ~6.37M shares (≈$16.5M). Insider purchases often signal confidence from management and can be supportive for the share price. SEC Form 4
• Neutral Sentiment: Short-interest data is inconsistent: a reliable report (as of Mar 13) showed short interest of 1,745,983 shares (≈9.9% of shares; days-to-cover ~5.7), which fell from late Feb levels — a positive for price stability — but multiple automated March 24 snapshots report 0 shorted shares (likely a data glitch). The conflicting feeds create uncertainty until exchanges/registrars confirm updated numbers.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on AFCG shares. Weiss Ratings restated a “sell (d)” rating on shares of AFC Gamma in a report on Wednesday, January 21st. Zacks Research lowered shares of AFC Gamma from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 5th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Sell” and an average price target of $4.50.

About AFC Gamma

AFC Gamma, Inc is a specialty finance real estate investment trust that focuses on providing structured financing solutions to companies operating and developing digital infrastructure and life science real estate assets. As a REIT, AFC Gamma seeks to generate attractive risk-adjusted returns through a diversified portfolio of loans, preferred equity and other financing structures that are secured by tangible property collateral or contractual revenue streams.

The company’s primary business activities include originating, acquiring and managing secured loans and equity investments that support wireless and broadband network deployment, data center expansion, and life sciences facility development.